| Literature DB >> 32194641 |
Dongying Zheng1,2,3,4,5, Yue Hou1,3,4,5, Yuanyuan Li1,3,4,5, Yue Bian1,3,4,5, Muhanmmad Khan6, Fan Li1,3,4,5, Ling Huang1,3,4,5, Chong Qiao1,3,4,5.
Abstract
Preeclampsia is a lethal pregnancy specific hypertensive disorder involving multisystem. Despite extensive studies to investigate the causes of preeclampsia, the pathogenesis still remains largely unknown. Long non-coding RNAs (lncRNAs) are a diverse class of non-translated RNAs which play a crucial part in various biological phenomena. Although lncRNA Growth Arrest-Specific 5 (GAS5) aberrantly expressed in multiple cancer tissues and is implicated in multiple biological processes of tumor cells, little is known about its role in preeclampsia. In this study, 40 patients with preeclampsia and 32 gestational age matched normotension pregnant women were recruited. Using quantitative real-time polymerase chain reaction (qRT-PCR), we found higher expression of GAS5 in placenta of preclamsia affected women. The level of GAS5 existed strongly in correlation with Thrombin Time indicating coagulation function and other clinical parameters by Pearson correlation analysis. Then we constructed the GAS5 lentivirus expression vectors and transfected into human trophoblast cell lines HTR-8/SVneo and JEG-3. Using in vitro cell culture studies, we found an inhibited effect of GAS5 on proliferative ability, migratory ability and invasive ability however; no effect on apoptosis was detected. Further mechanistic analysis found that GAS5 modulated microRNA-21 (miR-21) in an opposite variation tendency by qRT-PCR and rescue experiment. In addition, inhibition of GAS5 promoted the activation of PI3K/AKT signaling pathway and its downstream proteins covering MMP-9 and TP53 as evident from our qRT-PCR and western blot analyses. Thus, we suggested that GAS5 might involve in pregnancy with preeclampsia by influencing the biological functions of trophoblast cells through the regulation of miR-21 and activation of PI3K/AKT signaling pathway and its downstream targets, which may contribute to reveal the nature of preeclampsia.Entities:
Keywords: Gas5; early-onset; long non-coding RNA; miR-21; placenta; preeclampsia; trophoblast
Year: 2020 PMID: 32194641 PMCID: PMC7063462 DOI: 10.3389/fgene.2020.00188
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
Expression level of lncRNA GAS5, Clinical features and Laboratory parameters of the subjects.a
| ePE | eCON | lPE | lCON | |
| ( | ( | ( | ( | |
| GAS5 expression (2–ΔΔCT) | 1.74 ± 0.52c | 1.23 ± 0.79 | 1.29 ± 0.52d | 1.03 ± 0.24 |
|
| ||||
| Age (years) | 32.1 ± 4.1 | 30.3 ± 4.9 | 31.1 ± 5.0 | 30.3 ± 4.2 |
| Gravidityf | 2 (1∼4) | 3 (1∼6) | 2 (1∼4) | 2 (1∼3) |
| Parityf | 0 (0∼1) | 1 (0∼3) | 0 (0∼1) | 0 (0∼1) |
| Gestational age at delivery (weeks) | 31.6 ± 1.9c | 33.3 ± 1.8 | 37.0 ± 1.6d | 38.2 ± 1.0 |
| Expected treatment time (days) | 4.7 ± 3.8d | 3.1 ± 2.6 | 2.4 ± 2.1 | 1.9 ± 1.6 |
| Systolic blood pressure (mmHg) | 150.5 ± 25.3c | 112.7 ± 11.3 | 153.5 ± 15.4d | 118.0 ± 6.7 |
| Diastolic blood pressure (mmHg) | 95.6 ± 17.4c | 66.3 ± 6.0 | 103.4 ± 8.9d | 74.2 ± 6.5 |
|
| ||||
| Serum Total Protein (g/L) | 53.5 ± 6.0c | 62.9 ± 8.4 | 59.3 ± 7.9d | 64.1 ± 4.2 |
| Albumin (g/L) | 29.4 ± 3.8c | 33.9 ± 5.0 | 32.8 ± 4.9d | 36.9 ± 2.6 |
| Albumin/Globulin | 1.23 ± 0.17d | 1.18 ± 0.11 | 1.23 ± 0.17d | 1.36 ± 0.13 |
| ALT (U/L) | 19.8 ± 11.0c | 9.4 ± 5.5 | 15.2 ± 8.0 | 12.4 ± 5.6 |
| AST (U/L) | 23.4 ± 8.4c | 13.6 ± 5.6 | 22.3 ± 9.9d | 15.7 ± 5.0 |
| Blood urea nitrogen, (mmol/L) | 5.8 ± 2.1c | 3.1 ± 0.9 | 4.4 ± 1.1d | 2.9 ± 0.7 |
| Creatinine (μmol/L) | 60.9 ± 15.7d | 52.7 ± 9.5 | 55.7 ± 10.7d | 47.3 ± 8.1 |
| Urine acidity (pH value) | 6.46 ± 0.59 | 6.62 ± 0.77 | 6.31 ± 0.73d | 6.75 ± 0.62 |
| Proteinuriae | 3 (1∼4) | 1 (0∼4) | 2 (0∼4) | 0 (0∼1) |
| Urine specific gravity | 1.027 ± 0.01 | 1.025 ± 0.01 | 1.024 ± 0.01 | 1.023 ± 0.01 |
| Platelet (×109/L) | 148.4 ± 67.5c | 222.8 ± 74.3 | 182.8 ± 62.0 | 205.0 ± 54.7 |
| Hemoglobin (g/L) | 121.3 ± 23.4b | 106.2 ± 11.8 | 131.0 ± 18.4d | 116.5 ± 11.6 |
| Hematokrit (%) | 36.7 ± 7.3 | 31.9 ± 4.1 | 39.7 ± 5.9d | 35.6 ± 3.4 |
| TT, Thrombin time (s) | 15.7 ± 0.7c | 14.7 ± 0.5 | 15.3 ± 0.6d | 14.5 ± 0.3 |
| PT, Prothrombin time (s) | 9.6 ± 0.7c | 10.4 ± 0.5 | 9.8 ± 0.7d | 10.2 ± 0.5 |
| APTT (s) | 26.1 ± 2.8 | 26.0 ± 1.5 | 26.9 ± 2.3 | 26.9 ± 1.9 |
| Fibrinogen (g/L) | 3.7 ± 1.0d | 4.3 ± 1.2 | 4.5 ± 0.6 | 4.6 ± 0.7 |
| D-dimer (ng/mL) | 837.9 ± 992.4 | 931.7 ± 737.8 | 749.7 ± 397.7 | 806.5 ± 792.5 |
|
| ||||
| fT3, free triiodothyronine (pmol/L) | 4.0 ± 0.5d | 4.0 ± 0.3 | 4.1 ± 0.5 | 4.4 ± 0.6 |
| fT4, free thyroxine (pmol/L) | 9.6 ± 1.4d | 10.3 ± 1.4 | 10.1 ± 1.5d | 11.1 ± 1.1 |
| TSH (mIU/L) | 3.4 ± 2.3c | 1.5 ± 0.9 | 2.7 ± 1.3d | 1.8 ± 0.7 |
|
| ||||
| umbilical arteryflow S/D | 3.0 ± 0.8c | 4.3 ± 1.1 | 2.4 ± 0.4 | 2.4 ± 0.6 |
| Apgar scoref (1min) | 7 (0∼10) | 7 (3∼10) | 10 (7∼10) | 10 (9∼10) |
| Apgar scoref (5min) | 9 (7∼10) | 9 (7∼10) | 10 (9∼10) | 10 (10∼10) |
| Birth weight (g) | 1433.5 ± 463.9c | 2107.9 ± 370.7 | 2810.5 ± 781.0d | 3277.8 ± 420.0 |
FIGURE 1(A) The histogram showed the expression of GAS5 elevated in PE groups. The expression level of GAS5 was significantly higher in ePE compared to lCON and eCON. Respectively, the level of GAS5 was also significantly higher in lPE compared to lCON. (B) Scatter diagram showing correlation between GAS5 expression level and clinical parameters including TT, Albumin, Serum total protein and Fibrinogen. *P < 0.05, **P < 0.01, ***P < 0.001.
FIGURE 2(A) The green fluorescence in the dark field indicated the transfection efficiency of the two trophoblast cell lines. (B) The expression levels of GAS5 altered by lentiviral vectors in two cell lines. KD2 (GAS5) was selected for subsequent experiments as KD (GAS5) with the highest transfection efficiency. *P < 0.05, **P < 0.01, ***P < 0.001.
FIGURE 3(A) The MTT assay indicated that knockdown of GAS5 promoted the proliferation of trophoblast while overexpression of GAS5 inhibited the proliferative ability on the contrary. (B) With no significant incidence of apoptosis, GAS5 didn’t influence the apoptosis rate in both of the two cell lines. *P < 0.05, **P < 0.01, ***P < 0.001.
FIGURE 4(A) The Scratch test demonstrated the migration ability of two cell lines. Overexpression of GAS5 inhibited the migration of trophoblasts while knockdown GAS5 didn’t alter their migration ability. (B) Overexpression of GAS5 inhibited the invasion ability of trophoblasts according to transwell assay results, in the meanwhile, knockdown GAS5 didn’t alter their invation ability. *P < 0.05, **P < 0.01, ***P < 0.001.
FIGURE 5(A) After altered the expression of GAS5, the levels of miR-21 demonstrated the reverse tendency. (B) The effective transfection rate of miR-21 lentiviral vectors was shown. (C) The “rescue” experiment of co-transfection of GAS5 and miR-21 reversed the expression levels of GAS5 in two cell lines. (D) The co-transfection efficiency was observed by the green fluorescent in trophoblasts and was adequate for the subsequent experiment. *P < 0.05, **P < 0.01, ***P < 0.001.
FIGURE 6(A) Knockdown GAS5 promoted the activation of PI3K/AKT signaling pathway in the two cell lines. In HTR-8/SVneo, overexpression of GAS5 only inhibited the activation of PI3K not involving AKT, while in JEG-3, the PI3K/AKT pathway is not changed. All were analyzed by qRT-PCR assay. (B) We also detected the effect of GAS5 on PI3K/AKT pathway by Western Blot. In the two cell lines, knockdown GAS5 promoted the activation and overexpressed GAS5 inhibited this pathway except that the AKT in HTR-8/SVneo was not altered after GAS5 overexpressed, as same as the results detected by qRT-PCR in (A). The PTEN, which was suggested as a target gene of GAS5, was not altered by the two means (A,B). (C) The expression of downstream proteins involving MMP9 and TP53 were all elevated after GAS5 knockdown and declined after GAS5 overexpression, which were coincident with the variation of PI3K/AKT signaling pathway in HTR-8/SVneo, verified by qRT-PCR. *P < 0.05, **P < 0.01, ***P < 0.001.